XML 111 R86.htm IDEA: XBRL DOCUMENT
v3.25.0.1

BUSINESS COMBINATIONS - Narrative (Details) - USD ($) $ in Millions |  |  |  |  |  |  | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 01, 2024 | Sep. 30, 2024 | Aug. 19, 2024 | Aug. 18, 2024 | Jul. 22, 2024 | Feb. 28, 2023 | Dec. 31, 2024 | Sep. 30, 2024 | Dec. 31, 2024
Innovalve Bio Medical Limited |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Cash consideration paid at closing | $ 319.3 | $ 30.0 |  |  |  |  |  |  |
Fair value of previously held equity interest | $ 64.6 | $ 3.5 |  |  |  |  |  |  |
Percentage of previously held interest |  | 4.00% |  |  |  |  |  | 4.00% |
Equity interest in acquire, excluding initial acquisition, percentage | 96.00% |  |  |  |  |  |  |  |
Step acquisition, equity interest in acquire, remeasurement gain |  |  |  |  |  |  | $ 30.5 |  |
Total purchase price, net of cash acquired | $ 380.9 |  |  |  |  |  |  |  |
Payments to acquire businesses | 298.2 |  |  |  |  |  |  |  |
Cash acquired | 21.1 |  |  |  |  |  |  |  |
Settlement of pre-existing relationships | 5.4 |  |  |  |  |  |  |  |
Fair value of contingent consideration | 12.7 |  |  |  |  |  |  |  |
Additional milestone driven contingent consideration liability | $ 25.0 |  |  |  |  |  |  |  |
Milestone achievement period | 5 years |  |  |  |  |  |  |  |
Business combination, escrow deposit | $ 34.6 |  |  |  |  |  |  |  |
Acquisition-related costs |  |  |  |  |  |  |  |  | $ 2.3
Additional research and development expenditures to be incurred prior to product introduction | $ 74.3 |  |  |  |  |  |  |  |
Innovalve Bio Medical Limited | In-process research and development | Discount Rate |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Measurement input | 10.50% |  |  |  |  |  |  |  |
Endotronix, Inc |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Cash consideration paid at closing |  |  | $ 650.3 | $ 60.0 |  |  |  |  |
Fair value of previously held equity interest |  |  | $ 94.6 | $ 10.0 |  |  |  |  |
Percentage of previously held interest |  |  |  | 7.00% |  |  |  |  |
Equity interest in acquire, excluding initial acquisition, percentage |  |  | 93.00% |  |  |  |  |  |
Step acquisition, equity interest in acquire, remeasurement gain |  |  |  |  |  |  |  | $ 24.6 |
Total purchase price, net of cash acquired |  |  | $ 798.8 |  |  |  |  |  |
Payments to acquire businesses |  |  | 649.1 |  |  |  |  |  |
Cash acquired |  |  | 1.2 |  |  |  |  |  |
Settlement of pre-existing relationships |  |  | 53.1 |  |  |  |  |  |
Fair value of contingent consideration |  |  | 2.0 |  |  |  |  |  |
Business combination, escrow deposit |  |  | 35.0 |  |  |  |  |  |
Acquisition-related costs |  |  |  |  |  |  |  |  | 6.0
Additional research and development expenditures to be incurred prior to product introduction |  |  | $ 47.1 |  |  |  |  |  |
Endotronix, Inc | In-process research and development | Discount Rate |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Measurement input |  |  | 18.00% |  |  |  |  |  |
Endotronix, Inc | Developed technology | Discount Rate |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Measurement input |  |  | 15.50% |  |  |  |  |  |
JC Medical, Inc. |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Cash consideration paid at closing |  |  |  |  | $ 114.8 |  |  |  |
Total purchase price, net of cash acquired |  |  |  |  | 116.3 |  |  |  |
Cash acquired |  |  |  |  | 0.3 |  |  |  |
Fair value of contingent consideration |  |  |  |  | 1.8 |  |  |  |
Business combination, escrow deposit |  |  |  |  | 12.0 |  |  |  |
Acquisition-related costs |  |  |  |  |  |  |  |  | $ 1.6
Additional research and development expenditures to be incurred prior to product introduction |  |  | $ 55.8 |  |  |  |  |  |
Potential milestone-driven payments |  |  |  |  | $ 200.0 |  |  |  |
Contingent consideration liability, term |  |  |  |  | 12 years |  |  |  |
Escrow deposit, holding period |  |  |  |  | 15 months |  |  |  |
JC Medical, Inc. | In-process research and development | Discount Rate |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Measurement input |  |  |  |  | 15.00% |  |  |  |
Medical Technology Company |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Additional research and development expenditures to be incurred prior to product introduction |  |  |  |  |  | $ 68.6 |  |  |
Medical Technology Company | Variable Interest Entity, Primary Beneficiary |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Payments to acquire businesses |  |  |  |  |  | 169.0 |  |  |
Cash acquired |  |  |  |  |  | $ 6.8 |  |  |
Percentage of interest acquired |  |  |  |  |  | 61.00% |  |  |

X
- Definition Business Combination, Assets Acquired, Measurement Input + References No definition available. + Details
Name: | ew_BusinessCombinationAssetsAcquiredMeasurementInput
Namespace Prefix: | ew_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Consideration Transferred, Net Of Cash Acquired + References No definition available. + Details
Name: | ew_BusinessCombinationConsiderationTransferredNetOfCashAcquired
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Additional Liability + References No definition available. + Details
Name: | ew_BusinessCombinationContingentConsiderationAdditionalLiability
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Contingent Consideration, Liability, Term + References No definition available. + Details
Name: | ew_BusinessCombinationContingentConsiderationLiabilityTerm
Namespace Prefix: | ew_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Milestone Achievement Period + References No definition available. + Details
Name: | ew_BusinessCombinationContingentConsiderationMilestoneAchievementPeriod
Namespace Prefix: | ew_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Escrow Deposit + References No definition available. + Details
Name: | ew_BusinessCombinationEscrowDeposit
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Business Combination, Escrow Deposit, Holding Period + References No definition available. + Details
Name: | ew_BusinessCombinationEscrowDepositHoldingPeriod
Namespace Prefix: | ew_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, In-process Research and Development, Expected Costs + References No definition available. + Details
Name: | ew_BusinessCombinationInprocessResearchandDevelopmentExpectedCosts
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Business Combination, Settlement Of Pre-Existing Relationships + References No definition available. + Details
Name: | ew_BusinessCombinationSettlementOfPreExistingRelationships
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Step Acquisition, Equity Interest in Acquiree, Excluding Initial Acquisition, Percentage + References No definition available. + Details
Name: | ew_BusinessCombinationStepAcquisitionEquityInterestInAcquireeExcludingInitialAcquisitionPercentage
Namespace Prefix: | ew_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g)(1) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_CashAcquiredFromAcquisition
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ew_InnovalveBioMedicalLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ew_EndotronixIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ew_JCMedicalInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ew_MedicalTechnologyCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |